Hua Yunfen, Wu Yongqin, Guo Minjie, Ma Ruijing, Li Qingchuan, Hu Zheyuan, Chen Hongrui, Zhang Xingyu, Li Hui, Li Qingtian, He Ping
College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, China.
Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Front Microbiol. 2022 Jun 22;13:878800. doi: 10.3389/fmicb.2022.878800. eCollection 2022.
Carbapenem-resistant (CRKP), a pathogen that causes severe nosocomial infections and yields a high mortality rate, poses a serious threat to global public health due to its high antimicrobial resistance. Bacteriophages encode polysaccharide-degrading enzymes referred to as depolymerases that cleave the capsular polysaccharide (CPS), one of the main virulence factors of . In this study, we identified and characterized a new capsule depolymerase K19-Dpo41 from bacteriophage SH-KP156570. Our characterization of K19-Dpo41 demonstrated that this depolymerase showed specific activities against K19-type . K19-Dpo41-mediated treatments promoted the sensitivity of a multidrug-resistant K19-type strain to the bactericidal effect of human serum and significantly increased the survival rate of infected with K19-type . Our results provided strong primary evidence that K19-Dpo41 was not only effective in capsular typing of K19-type but promising in terms of developing new alternative therapeutic strategies against K19-type CRKP infections in the future.
耐碳青霉烯类肺炎克雷伯菌(CRKP)是一种可引发严重医院感染且死亡率很高的病原体,因其具有高度抗菌耐药性,对全球公共卫生构成严重威胁。噬菌体编码被称为解聚酶的多糖降解酶,这些酶可切割荚膜多糖(CPS),而荚膜多糖是肺炎克雷伯菌的主要毒力因子之一。在本研究中,我们从噬菌体SH-KP156570中鉴定并表征了一种新的荚膜解聚酶K19-Dpo41。我们对K19-Dpo41的表征表明,这种解聚酶对K19型肺炎克雷伯菌具有特异性活性。K19-Dpo41介导的处理提高了多重耐药K19型肺炎克雷伯菌菌株对人血清杀菌作用的敏感性,并显著提高了感染K19型肺炎克雷伯菌的小鼠的存活率。我们的结果提供了有力的初步证据,表明K19-Dpo41不仅在K19型肺炎克雷伯菌的荚膜分型中有效,而且在未来开发针对K19型CRKP感染的新替代治疗策略方面很有前景。